ACRS - Aclaris Therapeutics GAAP EPS of -$0.31 beats by $0.09 revenue of $1.45M misses by $0.22M May, 10 2022 07:20 AM Aclaris Therapeutics Inc. Aclaris Therapeutics press release (NASDAQ:ACRS): Q1 GAAP EPS of -$0.31 beats by $0.09. Revenue of $1.45M (-18.5% Y/Y) misses by $0.22M. For further details see: Aclaris Therapeutics GAAP EPS of -$0.31 beats by $0.09, revenue of $1.45M misses by $0.22M